The short version
- Why people research itA non-erythropoietic erythropoietin-receptor agonist for neuroprotection, neurite outgrowth, anti-inflammatory signaling and memory in animal models.
- What the evidence isThe trial missed its primary endpoints: no improvement in best-corrected visual acuity, central retinal thickness, central retinal sensitivity or tear production.
- What to watchBlood pressure climbing.
How Epobis works
Establish what this is before anything else, because the vendor's own title — Epobis (EPO) — invites the one mistake that matters. Erythropoietin is a 166-residue glycosylated cytokine that dimerizes its receptor.
The sequence, and the two things it tells you. Peptide catalogs list Epobis as the 18-mer NENITVPDTKVNFYAWKR — Asn-Glu-Asn-Ile-Thr-Val-Pro-Asp-Thr-Lys-Val-Asn-Phe-Tyr-Ala-Trp-Lys-Arg. That stretch checks out against the UniProt human EPO record (P01588): with the 27-residue signal peptide included, residues 63–80 are exactly NENITVPDTKVNFYAWKR, which is 36–53 of the mature 166-residue protein — the region after helix A running into the AB loop, consistent with a Site 1 contact surface.
EPO engages its receptor at two unequal sites — a high-affinity Site 1 and a low-affinity Site 2 — and dimerizes it, triggering Jak2/STAT5 and the survival cascades downstream. Working from the crystal structure of the EPO:EPOR2 complex, the Copenhagen group designed a peptide whose sequence encompasses amino acids from binding Site 1, and published it as a DENDRIMER: several copies on one backbone, because a single short peptide cannot reproduce the geometry of a receptor-dimerizing cytokine. The design goal is separation of function. Erythropoiesis needs full receptor engagement on erythroid progenitors, while tissue protection appears to run through a different receptor configuration, so a partial mimic can in principle keep neurite outgrowth, neuronal survival and anti-inflammatory signaling while losing the effect on red cell production. Both peptides from this program report exactly that: receptor binding and neuroprotection with no stimulation of erythropoiesis.
- Injectable
On the goal map: BDNF & neurotrophic signaling (Focus, memory & cognition)
Where to get Epobis
When a vetted partner does, the link and code go here.
Research on Epobis10 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Evidence on file: Theoretical — two papers from one Copenhagen group: an in vitro design and receptor-binding paper, and one rodent paper covering anti-inflammatory activity, blood-brain-barrier penetration, delayed onset of experimental autoimmune encephalomyelitis and improved social memory at 3 days. There is no human study of Epobis of any kind, no pharmacokinetics in any species and no published hematology numbers.
Human clinical evidence
No human study of Epobis exists. There is no human pharmacokinetic data.
And it is a different peptide. 8 completed. The trial missed its primary endpoints: no improvement in best-corrected visual acuity, central retinal thickness, central retinal sensitivity or tear production. It reported an improvement in a quality-of-life questionnaire score and improvements in some individual participants, no serious adverse events or reactions, and no anti-cibinetide antibodies. That is the honest state of human evidence for non-erythropoietic EPO peptides: one small trial, safe, negative on its primary outcomes.
Why the human EPO literature belongs on this page at all. The entire safety case for Epobis is the claim that it does NOT do what EPO does to red cells, so the consequences of being wrong are set by EPO's own human trials. In 4,038 patients with type 2 diabetes, chronic kidney disease and anemia, darbepoetin alfa targeting a hemoglobin of about 13 g/dL produced fatal or nonfatal stroke in 101 patients versus 53 on placebo, a hazard ratio of 1.92 (95% CI 1.38-2.68, p<0.001), with no reduction in either primary composite outcome. And in 1,233 hemodialysis patients with cardiac disease, targeting a hematocrit of 42% versus 30% gave 183 deaths versus 150 and 19 versus 14 nonfatal myocardial infarctions, risk ratio 1.3, and the study was halted with the conclusion that raising hematocrit to 42% is not recommended. Neither trial studied Epobis. They are here because they price the downside of the one claim this product rests on.
Correlative data
There is no human association or observational data for Epobis. What stands in its place is the design rationale, which is a published position rather than a result: EPO's neuroprotective, anti-inflammatory and antioxidative effects are well described, and the field's stated problem is that the use of EPO as a neuroprotective agent is hampered by its erythropoietic activity. That sentence is the reason this molecule exists.
A second group, working independently on the same problem from EPO helix C, states the class liability more bluntly still: the EPO-based therapeutic approach has side effects including hyper-erythropoietic and tumorigenic effects, which is why modified forms and derivatives have been proposed. Their lead peptide showed neuroprotection without inducing cell proliferation, attributed to a differential mode of EPO-receptor activation. Tumorigenicity is named in that abstract and has never been studied for Epobis.
The sibling peptide is the closest correlate Epobis has, and its potency number is the one to keep. Epotris, from the same Copenhagen laboratory, corresponds to the C-alpha-helix region (residues 92-111) of human erythropoietin. It bound the EPO receptor and promoted neurite outgrowth and neuronal survival with the same efficiency as erythropoietin but with 1,000-fold lower potency, penetrated the blood-brain barrier, attenuated seizures and reduced mortality and neurodegeneration in kainic-acid neurotoxicity, and did not stimulate erythropoiesis upon chronic administration. A thousand-fold potency gap is the price of replacing a glycosylated 166-residue cytokine with a peptide, and it is the number nobody selling these mentions.
How the mechanism reads
The design is structure-based and the paper says which face of the molecule it came from. EPO binds its receptor through a high-affinity Site 1 and a low-affinity Site 2, inducing conformational change and downstream signaling. From the crystal structure of the EPO:EPOR2 complex, the group designed a peptide whose sequence encompassed amino acids from binding Site 1, and named it Epobis. It is described as a synthetic, dendrimeric peptide derived from the sequence of human EPO that binds the EPO receptor and promotes neuritogenesis and neuronal cell survival.
MechanisticWhat has actually been shown, in order. In vitro: Epobis promotes neuritogenesis in primary motoneurons, and decreases TNF release from activated AMJ2-C8 macrophages and from rat primary microglia — two cell types, one a line and one primary. In vivo in rats: detectable in plasma and cerebrospinal fluid after systemic administration, so it crosses the blood-brain barrier; it delays the clinical signs of experimental autoimmune encephalomyelitis; and it has long-term but not short-term effects on working memory, detected as improved social memory 3 days after administration.
Experimental, animal or cellThe statement the whole product hangs on, quoted exactly as published: Epobis is not erythropoietic. That is asserted in the abstract of the one in vivo paper. What the abstract does NOT give is a hematocrit, a hemoglobin, a reticulocyte count, a duration or an n for that determination, and the full text could not be read here. The parallel claim for Epotris is phrased as not stimulating erythropoiesis upon chronic administration, which at least specifies the exposure. So the load-bearing safety claim for this class rests on two abstract-level assertions from one laboratory, and the underlying hematology has not been read.
MechanisticThe separation-of-function hypothesis, stated as the hypothesis it is. The reason a partial mimic might keep tissue protection while dropping erythropoiesis is that the two appear to run through different receptor configurations — full EPO-receptor homodimer engagement on erythroid progenitors versus an alternative receptor arrangement in other tissues. That framing is the field's, not this page's, and the independent helix-C program invokes a differential activating mode of EPOR signaling to explain neuroprotection without cell proliferation. It is a real, testable mechanism and it is also the convenient one, which is why the markers in the prediction section matter more than the argument.
Mechanistic
Sources
- Pankratova S, Gu B, Kiryushko D, Korshunova I, Kohler LB, Rathje M, Bock E, Berezin V. A new agonist of the erythropoietin receptor, Epobis, induces neurite outgrowth and promotes neuronal survival. Journal of Neurochemistry 2012;121(6):915-23 · PMID 22469063
- Dmytriyeva O, Pankratova S, Korshunova I, Walmod PS. Epobis is a Nonerythropoietic and Neuroprotective Agonist of the Erythropoietin Receptor with Anti-Inflammatory and Memory Enhancing Effects. Mediators of Inflammation 2016;2016:1346390 · PMID 27990061
- Pankratova S, Kiryushko D, Sonn K, Soroka V, Kohler LB, Rathje M, Gu B, Gotfryd K, Clausen O, Zharkovsky A, Bock E, Berezin V. Neuroprotective properties of a novel, non-haematopoietic agonist of the erythropoietin receptor. Brain 2010;133(Pt 8):2281-94 · PMID 20435631
- Cho B, Yoo SJ, Kim SY, Lee CH, Lee YI, Lee SR, Moon C. Second-generation non-hematopoietic erythropoietin-derived peptide for neuroprotection. Redox Biology 2022;49:102223 · PMID 34953452
- Lois N, Gardner E, McFarland M, Armstrong D, McNally C, Lavery NJ, Campbell C, Kirk RI, Bajorunas D, Dunne A, Cerami A, Brines M. A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema. Journal of Clinical Medicine 2020;9(7):2225 · PMID 32674280
- Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. New England Journal of Medicine 2009;361(21):2019-32 · PMID 19880844
- Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. New England Journal of Medicine 1998;339(9):584-90 · PMID 9718377
Epobis safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Active cancer, as erythropoietin-receptor signaling is used by tumor cells.
- A history of blood clots or stroke.
- High hematocrit or polycythemia.
- Uncontrolled hypertension.
- Pregnancy, since erythropoietin-receptor agonists alter placental blood flow.
What’s expected
- Neuroprotective signaling without the red-cell rise of erythropoietin, the claim to verify.
- Mild headache as vessels respond to an EPO-receptor agonist.
- Site soreness.
Watch for
- Blood pressure climbing.
- A painful swollen calf or sudden shortness of breath.
- Sudden severe headache with vision change, a stroke or pressure warning.
Labs that tell you it’s working
- Complete Blood Count: hematocrit and hemoglobin must NOT rise, which tests the non-erythropoietic design.
- Ferritin: an EPO-like drive would draw iron stores down.
- hs-CRP: the repair-receptor anti-inflammatory claim.
18-residue peptide built from the erythropoietin binding face; designed to signal through tissue-protective receptors without red-cell effects. PMID 22469063 PMID 27990061 PMID 34953452
Bloodwork to runHow you would know it is working: 9 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
Epobis FAQ4 common questions
- Is Epobis approved for human use?
- No. Epobis is a research compound.
- What is Epobis researched for?
- A non-erythropoietic erythropoietin-receptor agonist for neuroprotection, neurite outgrowth, anti-inflammatory signaling and memory in animal models.
- Which labs show whether it's doing anything?
- Complete Blood Count; Ferritin; hs-CRP: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for Epobis: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.



